Sugi Predict

Sugi Predict / Compounds / SCHEMBL55596

SCHEMBL55596

SCHEMBL55596

C[C@H](CCC(=O)NCCC[N+](C)(C)CCCS(=O)(=O)O)[C@H]1CCC2C3CCC4CCCC[C@]4(C)C3CC[C@@]21C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHA2 P29317 3/20 0.68
▸ GPBAR1 Q8TDU6 12/20 0.64
▸ ABCC4 O15439 5/20 0.64
▸ VDR P11473 2/20 0.64
▸ NR1H4 Q96RI1 3/20 0.63
▸ AKR1B10 O60218 1/20 0.59
▸ AKR1B1 P15121 1/20 0.59
▸ EFNA1 P20827 1/20 0.59
▸ PSEN1 P49768 1/20 0.59
▸ PSEN2 P49810 1/20 0.59
▸ APH1B Q8WW43 1/20 0.59
▸ NCSTN Q92542 1/20 0.59
▸ APH1A Q96BI3 1/20 0.59
▸ PSENEN Q9NZ42 1/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ ST6GAL1 P15907 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18045259 0.93 EPHA2 (0.67) EPHA2GPBAR1ABCC4VDRNR1H4
SCHEMBL58082 0.93 EPHA2 (0.67) EPHA2GPBAR1ABCC4VDRNR1H4
SCHEMBL4777980 0.93 EPHA2 (0.67) EPHA2GPBAR1ABCC4VDRNR1H4
SCHEMBL1697054 0.93 EPHA2 (0.76) EPHA2GPBAR1ABCC4VDRNR1H4
Water SCHEMBL278724 0.92 EPHA2 (0.66) EPHA2GPBAR1ABCC4VDRNR1H4
Water SCHEMBL8333417 0.92 EPHA2 (0.66) EPHA2GPBAR1ABCC4VDRNR1H4
Sulfuric Acid SCHEMBL5587293 0.92 EPHA2 (0.68) EPHA2GPBAR1ABCC4VDRNR1H4
SCHEMBL6857975 0.92 EPHA2 (0.75) EPHA2GPBAR1ABCC4VDRNR1H4
SCHEMBL6065533 0.91 EPHA2 (0.66) EPHA2GPBAR1ABCC4VDRNR1H4
Sulfuric Acid SCHEMBL10535471 0.91 EPHA2 (0.68) EPHA2GPBAR1ABCC4VDRNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11977072-B2 Solution-based plasmonic specific-binding partner assays using metallic nanostructures ZOETIS SERVICES LLC (US) 2024-05-07 — — US claimed
CN-115074425-A Imaging reagent and kit for fluorescence-based multi-cycle nucleic acid sequencing reaction 郑州思昆生物工程有限公司 2022-09-20 — — CN claimed
US-11215614-B2 Signal amplification in solution-based plasmonic specific-binding partner assays ZOETIS SERVICES LLC (US) 2022-01-04 — — US claimed
US-20200110086-A1 SIGNAL AMPLIFICATION IN SOLUTION-BASED PLASMONIC SPECIFIC-BINDING PARTNER ASSAYS ABAXIS LLC 2020-04-09 — — US claimed
US-20200032163-A1 Method for the Virus Inactivation of a Preparation of Monoclonal Antibodies LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR) 2020-01-30 — — US claimed
WO-2018140953-A1 SOLUTION-BASED PLASMON SPECIFIC-BINDING PARTNER ASSAYS AND METALLIC NANOSTRUCTURES ABAXIS, INC. (US) 2018-08-02 — — WO claimed
EP-2652147-B1 ONE-STEP METHOD OF ELUTION OF DNA FROM BLOOD SAMPLES WISCONSIN ALUMNI RES FOUND (US) 2017-01-25 — — EP claimed
US-9206468-B2 One-step method of elution of DNA from blood samples WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-12-08 — — US claimed
US-9110058-B2 Porous solid phase for binding assay, and binding assay method using the same SEKISUI MEDICAL CO., LTD. (JP) 2015-08-18 — — US claimed
US-20150191800-A1 DETECTION OF CYTOMEGALOVIRUS DNA USING AMPLIFICATION FROM BLOOD SAMPLES NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2015-07-09 — — US claimed
WO-2012037394-A1 STABILIZATION OF OZONE-LABILE FLUORESCENT DYES BY THIOUREA IBIS BIOSCIENCES, INC. (US) 2012-03-22 — — WO claimed
US-20120070830-A1 STABILIZATION OF OZONE-LABILE FLUORESCENT DYES BY THIOUREA lbis Biosciences, Inc. (US) 2012-03-22 — — US claimed
US-20100035331-A1 METHOD FOR EXTRACTING OF NUCLEIC ACID FROM BIOLOGICAL MATERIAL TOSOH CORPORATION (JP) 2010-02-11 — — US claimed
EP-1992689-A1 METHOD FOR EXTRACTION OF NUCLEIC ACID FROM BIOLOGICAL MATERIAL Tosoh Corporation (JP) 2008-11-19 — — EP claimed
US-7250269-B2 Composition for assaying glycoprotein ASAHI KASEI PHARMA CORPORATION (JP) 2007-07-31 — — US claimed
US-20060141556-A1 Microwave cell lysis method using ionic additives JEONG SUNG-YOUNG 2006-06-29 — — US claimed
US-6130055-A MEASURING URINARY TRYPSIN INHIBITOR EASILY AND QUICKLY AT HIGH SENSITIVITY BY MIXING SAMPLE, TYPSIN OR CHYMOTRYPSIN, SYNTHETIC SUBSTRATE, AND SURFACTANT; MEASURING PROTEASE ACTIVITY; AND DETERMINING CONCENTRATION OF INHIBITOR KYOTO DAIICHI KAGAKU CO., LTD. (JP) 2000-10-10 — — US claimed
US-5856117-A MIXING URINE SAMPLE WITH PROTEASE SOLUTION CONTAINING BUFFER KYOTO DAIICHI KAGAKU CO., LTD. (JP) 1999-01-05 — — US claimed
US-5676931-A DRUG DELIVERY ABBOTT LABORATORIES (US) 1997-10-14 — — US claimed
US-5252463-A Measuring protease inhibition of a protein THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-10-12 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070830-A1 STABILIZATION OF OZONE-LABILE FLUORESCENT DYES BY THIOUREA HNRNPU, STAU1, TCOF1 EPHA2 1069/4885GPBAR1 4319/4885ABCC4 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.